Jim Cramer's Mad Dash: Is Bristol-Myers in Trouble?
NEW YORK (TheStreet) -- Bristol-Myers Squibb
Regarding the rating change, he called it "a downgrade that is going to send quivers through people."
The downgrade matters because it specifically questions the company's cancer applications pipeline, Cramer said, adding that Bristol-Myers is highly valued compared to its peers.
Cramer admitted to liking shares of Bristol-Myers, but suggested that investors read the downgrade report -- as will he, for the second time.
Turning to Plug Power
The stock just did a "gigantic" secondary offering, Cramer said, and reiterated that he is not a buyer of the stock.
-- Written by Bret Kenwell in Petoskey, Mich.
>>Read More: Cisco Surges on Earnings Beat, Eyes Growth
>>Read More: It's Not Too Late to Detach From Plug Power